Today’s 13GD Alert: Zogenix, Inc Has Another Bullish Trade, Walters William T Bought Stake!

Today's 13GD Alert: Zogenix, Inc Has Another Bullish Trade, Walters William T Bought Stake!

The New Walters William T Holding in Zogenix, Inc

Walters William T filed with the SEC SC 13G form for Zogenix, Inc. The form can be accessed here: 000114036116086944. As reported in Walters William T’s form, the filler as of late owns 8.1% or 2,000,000 shares of the Health Care–company.

Zogenix, Inc stake is a new one for the and it was filed because of activity on July 26, 2016. We feel this shows Walters William T’s positive view for the stock.

Business Profile

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

About 167,734 shares traded hands. Zogenix, Inc. (NASDAQ:ZGNX) has risen 12.00% since April 14, 2016 and is uptrending. It has outperformed by 7.31% the S&P500.

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The company has a market cap of $298.73 million. The Company’s areas of focus are epilepsy and schizophrenia. It currently has negative earnings. The Company’s lead product candidate, ZX008, is a low-dose fenfluramine.

Zogenix, Inc. (NASDAQ:ZGNX) Ratings Coverage

Out of 3 analysts covering Zogenix (NASDAQ:ZGNX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $28 is the highest target while $22 is the lowest. The $25.40 average target is 110.79% above today’s ($12.05) stock price. Zogenix has been the topic of 8 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Brean Capital maintained Zogenix, Inc. (NASDAQ:ZGNX) rating on Thursday, September 17. Brean Capital has “Buy” rating and $28 price target. The firm has “Buy” rating by Brean Capital given on Friday, August 14. The stock has “Outperform” rating given by Leerink Swann on Tuesday, August 11. Zacks upgraded the stock to “Hold” rating in Saturday, August 15 report. The firm earned “Sell” rating on Thursday, August 6 by Zacks.

More recent Zogenix, Inc. (NASDAQ:ZGNX) news were published by: Fool.com which released: “Zogenix, Inc Gained 29% in 2015 — Here’s Why” on January 14, 2016. Also Fool.com published the news titled: “Why Zogenix, Inc. Shares Were Throttled” on April 27, 2015. Fool.com‘s news article titled: “Why Zogenix, Inc. Shares Rocketed 22% Higher in May” with publication date: June 05, 2015 was also an interesting one.

According to Zacks Investment Research, “Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA.”

ZGNX Company Profile

Zogenix, Inc., incorporated on May 11, 2006, is a pharmaceutical firm engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. The Company’s lead product candidate, ZX008, is a low-dose fenfluramine. The Firm is also engaged in the development of Relday. It is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, under an Asset Purchase Agreement with Endo Ventures Bermuda Limited and Endo Ventures Limited (collectively, Endo). The Firm sells Sumavel DosePro to Endo.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment